Hawaii Biotech is focused on developing innovative medical countermeasures and vaccines to combat infectious diseases. The company is advancing small molecule drug candidates aimed at treating Anthrax and botulism, while also working on a recombinant subunit protein vaccine pipeline that targets both emerging and re-emerging infectious diseases. Their proprietary stable insect cell vaccine platform enables the production of high-quality proteins that maintain a native-like structure, which have been shown to elicit robust immune responses. Additionally, Hawaii Biotech has developed a semi-synthetic saponin adjuvant, GPI-0100, to enhance immune responses for both vaccines and therapeutics.

The company is also engaged in the development of vaccines for viral hemorrhagic fevers, including those caused by filoviruses and Bunyavirales. They have patented recombinant glycoproteins from viruses such as Ebola and Marburg, which are being formulated into individual and multivalent vaccines. Collaborations with academic institutions have led to promising advancements, such as a thermal-stable Ebola vaccine suitable for global distribution. Furthermore, Hawaii Biotech is addressing the urgent need for vaccines against other significant pathogens, including the Crimean-Congo hemorrhagic fever virus and various alphaviruses, by leveraging their recombinant subunit approach to create safe and effective vaccine candidates.

United States

Hawaii Biotech, Inc. (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases.

Hawaii Biotech

Company Details